|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Time to End of Next-Line Therapy in the JAVELIN Bladder 100 |
| Petros Grivas, MD, Ph.D. |
| This conversation with Alicia Morgans, Petros Grivas highlights a post hoc analysis of the JAVELIN Bladder 100 trial which further characterizes the efficacy of avelumab first-line maintenance of time to end of next-line therapy. |
|
|
|
|
|
|
|
|
|
|
|
| Feladilimab Alone and in Combination with Pembrolizumab In Previously-Treated Urothelial Carcinoma Patients, An expansion Cohort of the INDUCE-1 Trial |
| Arjun Balar, MD |
| Arjun Balar joins Alicia Morgans in a discussion on INDUCE-1, the a first-in-human trial evaluating feladilimab as monotherapy and in combination with pembrolizumab. |
|
|
|
|
|
|
|
|
|
|
|
| First-Line Pembrolizumab (Pembro) in Cisplatin-Ineligible Patients with Advanced Urothelial Cancer (UC): Response and Survival Results up to Five Years from the KEYNOTE-052 Phase 2 Study |
| Peter O’Donnell, MD |
| The KEYNOTE-052 study led to the approval of pembrolizumab for the first-line treatment of cisplatin-ineligible patients with advanced urothelial carcinoma. In this presentation, Dr. Peter O’Donnell presented updated results of 5 years of follow-up, with the median time from enrollment to data cutoff of 56.3 months. |
|
|
|
|
|
|
|
|
|
|
| Avelumab First-Line Maintenance plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma: Analysis of Time to End of Next-Line Therapy in JAVELIN Bladder 100 |
| Petros Grivas, MD, Ph.D. |
| To further characterize the efficacy benefits of avelumab first-line maintenance, Petros Grivas reports results of a post hoc analysis of time to end of next-line therapy (for any reason) in the randomized trial population. These data provide further evidence of the efficacy of a maintenance approach with avelumab in patients with advanced urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy. |
|
|
|
|
|
| Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Analysis of Clinical and Genomic Subgroups from the JAVELIN Bladder 100 Trial |
| Thomas Powles, MD, MBBS, MRCP |
| Thomas Powles presents results of post hoc analyses in previously unreported clinical and genomic subgroups of the JAVELIN Bladder 100 Trial. An OS and PFS benefit was seen for avelumab first-line maintenance + best supportive care versus best supportive care alone across subgroups of interest, including patients with upper or lower tract disease, metastatic disease, unresectable locally advance disease, or lymph node-only disease, PD-L1 positive tumors who received first-line gemcitabine + carboplatin, and tumor genomic subtypes defined by the TCGA. |
|
|
|
|
|
| Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial: Subgroup Analysis by Duration of Treatment-Free Interval from End of Chemotherapy to Start of Maintenance |
| Srikala Sridhar MD, MSc, FRCPC |
| Srikala Sridhar presents results of a post hoc analysis assessing efficacy by duration of the treatment-free interval from completion of first-line chemotherapy. In patients with advanced urothelial carcinoma that had not progressed with first-line platinum-containing chemotherapy, avelumab first-line maintenance prolonged OS irrespective of the treatment-free interval assessed in this study (4-10 weeks), supporting this new treatment strategy as a standard of care. |
|
|
|
|
|
| Impact of Recurrence On Health-Related Quality of Life In Patients at High Risk of Recurrence After Radical Surgery For Muscle-Invasive Urothelial Carcinoma: Results From the Phase 3 CheckMate 274 Trial |
| Matt Galsky, MD |
| Matt Galsky presented results of a post hoc analysis assessing the impact of recurrence on HRQoL using data from the phase 3 CheckMate 274 trial. Recurrence, particularly distant recurrence, had a significant, negative impact on HRQoL. This suggests that treatment delaying recurrence after radical surgery for high-risk muscle-invasive urothelial carcinoma may prevent or delay HRQoL deterioration in these patients. |
|
|
|
|
|
| A Randomized Phase II Study Comparing Cisplatin and Gemcitabine with or Without Berzosertib in Patients with Advanced Urothelial Carcinoma |
| Sumanta Pal, MD |
| Cisplatin and gemcitabine is a first line chemotherapy option for patients with metastatic urothelial carcinoma who are medically eligible to receive cisplatin. These chemotherapies induced DNA damage through distinct mechanisms, and it stands to reason that further disruption of DNA break repair may augment the efficacy of these agents. As the ATR (ataxia telangiectasia and Rad3-related) gene responds to DNA single-strand breaks, inhibiting this protein may provide additional benefit to patients. |
|
|
|
|
|
| Inducible T-Cell Co-Stimulatory Receptor Agonist, Feladilimab, Alone and in Combination With Pembrolizumab: Results From INDUCE-1 Urothelial Carcinoma Expansion Cohorts |
| Arjun Balar, MD |
| Arjun Balar presents results of a study assessing preliminary efficacy, safety, and biomarker data of feladilimab ± pembrolizumab in INDUCE-1 urothelial carcinoma expansion cohorts. Feladilimab demonstrated evidence of clinical activity as monotherapy in heavily pre-treated, PD-(L)-1-experienced advanced urothelial carcinoma and in combination with pembrolizumab in anti-PD-(L)-1-naïve advanced urothelial carcinoma. |
|
|
|
|
|
|
|
|
|
|
|
